Holding(s) in Company

RNS Number : 7960D

Circassia Pharmaceuticals Plc

01 April 2014

 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

Circassia Pharmaceuticals PLC

2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights		X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):

3. Full name of person(s) subject to the notification obligation: iii	OppenheimerFunds, Inc.
4. Full name of shareholder(s) (if different from 3.): iv
5. Date of the transaction and date on which the threshold is crossed or reached: v	28 March 2014
6. Date on which issuer notified:	31 March 2014
7. Threshold(s) that is/are crossed or reached: vi, vii	5% (increased to 5.72%)

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of  voting rights x
			Direct	Direct xi	Indirect xii	Direct	Indirect
GB00BJVD3B28	9,000,000	9,000,000	10,805,820		10,805,820		5.72%

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration date xiii	Exercise/ Conversion Period xiv	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date xvii	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	% of voting rights xix, xx
					Nominal	Delta

Total (A+B+C)
Number of voting rights	Percentage of voting rights
188,786,254	5.72%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

OppenheimerFunds, Inc. ("OFI") is a registered investment advisor with the U.S. SEC.  Its ultimate parent company, Massachusetts Mutual Life Insurance Company, qualifies for disaggregation under FCA regulations.  The shares of the issuer are held by investment accounts managed by OFI.

Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:
14. Contact name:	Julien Cotta Chief Financial Officer
15. Contact telephone number:	[phone]

Note: Annex should only be submitted to the FCA not the issuer
Annex: Notification of major interests in share
A: Identity of the persons or legal entity subject to the notification obligation
Full name (including legal form of legal entities)
Contact address (registered office for legal entities)
Phone number & email
Other useful information (at least legal representative for legal persons)
B: Identity of the notifier, if applicable
Full name
Contact address
Phone number & email
Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)
C: Additional information
For notes on how to complete form TR-1 please see the FCA website.

 

END

 

 

HOLUAONRSAASRAR